Drug Trial Radar · NCT01360632
Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)
Last checked: Nov 20, 2026Latest source record: Jan 1, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,539
Actual
Start
Jun 2011
Primary completion
Aug 2013
Study completion Sep 2013
Sponsor
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
- Sponsor type
- Industry
- First posted
- May 25, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To compare the effect of OPC-34712 (brexpiprazole) to the effect of placebo (an inactive substance) as add on treatment to an assigned FDA approved antidepressant treatment (ADT) in patients with Major Depressive Disorder who demonstrate an incomplete response to a prospective trial of the same assigned FDA approved ADT
Conditions
- Depressive Disorder
- Depression
- Depressive Disorder, Major
- Mood Disorders
- Mental Disorders
Interventions
OPC-34712 + ADTDrug
Tablets, Oral, 1 or 3 mg OPC-34712 and FDA Approved Antidepressant Therapy (ADT)
Placebo + ADTDrug
Placebo + FDA Approved Antidepressant (ADT)
Placebo + ADTDrug
Placebo + FDA Approved Antidepressant (ADT)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change From the End of Phase A (Week 8 Visit) to Phase B (Week 14 Visit) in the Montgomery-Asberg Depression Rating Scale for the Efficacy Sample SetTime frame: Baseline and Week 14
- Mean Change in MADRS Total Score From Baseline End of Week 8 to Week 14 for the Efficacy Sample Per Final ProtocolTime frame: Baseline and Week 14
Locations
71 sites in 7 countries. Site status is shown where the registry gives one.
Research Site
Birmingham, Alabama
Research Site
Costa Mesa, California
Research Site
Glendale, California
Research Site
Orange, California
Research Site
San Diego, California
Research Site
Temecula, California
Research Site
Jacksonville, Florida
Research Site
Jacksonville Beach, Florida
Research Site
Miami Springs, Florida
Research Site
Tampa, Florida
Research Site
Winter Park, Florida
Research Site
Atlanta, Georgia
Research Site
Smyrna, Georgia
Research Site
Chicago, Illinois
Research Site
Oak Brook, Illinois
Research Site
Lafayette, Indiana
Research Site
Owensboro, Kentucky
Research Site
Baltimore, Maryland
Research Site
Haverhill, Massachusetts
Research Site
Weymouth, Massachusetts
Research Site
Rochester Hills, Michigan
Research Site
Creve Coeur, Missouri
Research Site
Las Vegas, Nevada
Research Site
Cherry Hill, New Jersey
Research Site
Toms River, New Jersey
Research Site
Brooklyn, New York
Research Site
Fresh Meadows, New York
Research Site
New York, New York
Research Site
Staten Island, New York
Research Site
Raleigh, North Carolina
Research Site
Beachwood, Ohio
Research Site
Cincinnati, Ohio
Research Site
Columbus, Ohio
Research Site
Oklahoma City, Oklahoma
Research Site
Portland, Oregon
Site not named
Salem, Oregon
Research Site
Norristown, Pennsylvania
Research Site
Philadelphia, Pennsylvania
Research Site
Lincoln, Rhode Island
Research Site
Columbia, South Carolina
Showing 40 of 71 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.